Anthelmintic Drugs Market Size, Share, Growth, Trends, Consumption, Revenue, Company Analysis and Forecast 2020-2027

Global anthelmintic drugs market size surpassed at US$ 2.1 Bn in 2019 and is projected to grow at a CAGR of 4.8% during the forecast period 2020 to 2027.

The global anthelmintic drugs market size is projected to surpass around US$ 3.8 billion by 2027, increase in incidence of helminth infection across the globe, innovative drug launch for gastrointestinal nematodes, government initiatives, and rise in pet ownership and spending on companion animals are expected to drive the global market during the forecast period.

Anthelmintic drugs are the group of the antiparasite drugs recommended for the treatment of the helminths in the body. Anthelmintic drugs are used to remove the parasitic forms, such as roundworm, flatworm, whipworm, and pinworm from animals and humans. Apart from infecting humans, the helminthic worms widely impact the livestock, companion animals, and other animals, which is likely to drive the anthelmintic drugs market.

The global anthelmintic drugs market is driven by rise in prevalence of human and animal helminthic infections across globe, availability of various generics medicines, government establishing guidelines for eradication of worm infections, efforts on increasing awareness about helminthic infections, and rising incidence of ascariasis across subtropical region, including countries in Africa and Asia. These factors are likely to propel the anthelmintic drugs market across the globe. As per the WHO estimation in 2019, around 1.5 to 2 billion people were suffering from soil-transmitted helminth infections.

Europe dominated the global anthelmintic drugs market in 2019, followed by Asia Pacific and the trend is anticipated to continue during the forecast period. The region’s dominance can be ascribed to the presence of key veterinary as well as human anthelmintic drugs manufacturers, large veterinary business in the countries in Europe, and high awareness about veterinary animal health.

Increase in Prevalence of Helminthic Infections to Drive Global Market

The growing incidence of helminthic infections among animals and humans is anticipated to propel the demand for anthelmintic drugs across the globe. According to the WHO, 1.5 billion people were suffering from soil-transmitted helminth infections in March 2020, which accounted for 24% of the world’s population. Hookworm, ascaris, and whipworm accounted for the largest soil-transmitted helminths burden across the globe. According to CDC estimates, in 2019, 807 million to 1,221 million people across the world were infected by ascaris, and around 604 million to 795 million are likely to suffer from whipworm globally. In the U.S., according to the CDC, pinworm is the most common helminth infection, with prevalence of 0.2% to 20% in children.

Globally, 200 million people are affected by enterobius vermicularis (pinworms), accounting for 30% of the cases globally. Children in the age group of 5 to 10 years are most susceptible to this infection. Furthermore, as per the CDC, 2,800 cases of angiostrongylus cantonensis across 30 countries have been reported in 2018. According to a research conducted in 2019, prevalence of roundworms in dogs ranged from 1.8% to 5.0%, hookworm infection was estimated to be around 2.5% to 4.5%, and whipworm infection was reported to be around 0.8% to 1.2%.

Anthelmintic Drug Resistance to Hamper Market

• Anthelmintic drugs are the most preferred and efficient treatment for fighting helminthiasis in animals and humans. However, multidrug-resistance is a major concern in livestock, especially in the two new classes such as aminoacetonitrile derivatives and paraherquamide derivatives.
• Rise in multidrug-resistance would pressurize producers and animal health professionals to develop alternative methods of treatment. Thus, rise in drug resistance to most commonly prescribed anthelmintic drugs by parasitic helminths is likely to restrain the market during the forecast period. Helminthiasis has been reported to develop resistance to drugs such as Levamisole, morantel, Benzimidazole, Albendazole, Avermectin, and Ivermectinin the past few years.
• Resistance to anthelmintic drugs is a major concern in sheep-producing countries in Europe. Multidrug & multispecies resistance is increasing at a rapid pace in South America. This is anticipated to restrain the global anthelmintic drugs market. According to a research, resistance against monepantel and derquantel has already been reported, which has increased the risk factor associated with anthelmintic resistance.

Key Drivers

• Rise in prevalence of helminth infections caused by roundworm, hookworm, whipworm, and others worms is anticipated to drive the need of anthelmintic drugs for the treatment of the same
• Soil transmitted helminth infections are caused by various species of parasitic worms. According to the WHO, as of March 2020, nearly 1.5 billion humans were suffering from soil transmitted helminth infection across the globe. This number accounts for 24% of the global human population. Major species increasing the disease burden are ascaris lumbricoides (roundworms), trichuris trichiura (whipworms), necator americanus, and ancylostoma duodenale (hookworms).
• According to the WHO data, in March 2020, distribution of soil-transmitted helminth infection was higher in sub-Saharan Africa, the Americas, China, and countries in Asia. Globally, 267 million preschool children and 568 million schoolchildren in the above areas are suffering from helminth infections.
• Moreover, S. stercoralis are estimated to be affecting around 600 million people globally. Poor hygiene and sanitation are the other factors boosting incidence of soil-transmitted helminth infections across the globe.

Prominent Regions

In terms of region, the global anthelmintic drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe dominated the global anthelmintic drugs market in 2019, followed by Asia Pacific. The number of companion animals in the region is increasing at a higher rate, as compared to that of livestock animals, due to rise in pet ownership and the presence of key players offering anthelmintic drugs. This, in turn, is estimated to boost the market in the region. The anthelmintic drugs market in Asia Pacific is likely to expand at a highest CAGR from 2020 to 2030. The growth of the market in the region can be attributed to a large veterinary industry in China, Australia, and New Zealand; rise in pet care expenditure; increase in demand for animal care; and surge in veterinary hospitals and clinics in China, India, South Korea, and Hong Kong. As per research, prevalence of hookworm infections in the population was estimated to be 19% in July 2018 in countries in Asia Pacific.

Leading players operating in the global anthelmintic drugs market include 

• Novartis AG
• Cipla Inc.
• Sun Pharmaceutical Industries Ltd
• Amneal Pharmaceuticals LLC. (Impax Laboratories, Inc.)
• Zoetis, Inc.
• GlaxoSmithKline plc
• Bayer AG
• Merck & Co., Inc. (Intervet Inc.)
• Boehringer Ingelheim International GmbH

Market Segmentation

By Drug Class

• • Benzimidazoles
  • Piperazine
  • Others

By Route of Administration

• • Oral
  • Injectable

By Application

• • Human
    • Parenchymal Neurocysticercosis
    • Gastrointestinal Infections
  • Animal

By Target Pathogen

• • Ascaris Lumbricoides (Roundworm)
  • Trichuris Trichiura (Whipworm)
  • Enterobius Vermicularis (Pinworm)
  • Ancylostoma Duodenale (Hookworm)
  • Others

By Distribution Channel

• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Veterinary Pharmacies
  • Veterinary Hospitals and Clinics

By Region

• • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa